Biocryst Pharmaceuticals (BCRX) Debt Ratio (2011 - 2026)

Biocryst Pharmaceuticals' Debt Ratio history runs 16 years deep, the most recent figure standing at 0.94 for Q1 2026.

• Quarterly Debt Ratio rose 28.55% year-over-year to 0.94 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 0.94 (up 28.55% YoY) and the FY2025 annual result came in at 0.07, down 89.45% from the prior year.
• Debt Ratio was 0.94 for Q1 2026 at Biocryst Pharmaceuticals, up from 0.07 in the prior quarter.
• Across five years, Debt Ratio topped out at 0.94 in Q1 2026 and bottomed at 0.07 in Q4 2025.
• A 5-year average of 0.55 and a median of 0.57 in 2023 frame the typical range for Debt Ratio.
• Annual changes were most pronounced in 2023 — Debt Ratio jumped 95.46% — and 2025, when it plunged 89.45%.
• Biocryst Pharmaceuticals' Debt Ratio stood at 0.42 in 2022, then soared by 50.11% to 0.63 in 2023, then increased by 12.1% to 0.71 in 2024, then plunged by 89.45% to 0.07 in 2025, then surged by 1152.12% to 0.94 in 2026.
• Business Quant data shows BCRX's Debt Ratio at 0.94 in Q1 2026, 0.07 in Q4 2025, and 0.52 in Q3 2025.